The company was issued U.S. patent No. 10,997,716 for SubtleGAD, which is said to reduce the gadolinium dosage by 90% while maintaining high-quality diagnostic MRI images. Currently in the investigational phase, the software uses proprietary deep-learning algorithms to achieve equivalent diagnostic image quality using only 10% of the gadolinium contrast dose.
Subtle Medical claims that SubtleGAD can reduce gadolinium dosage by 90%. Image courtesy of Subtle Medical.